MIF: Mood Improving/Inhibiting Factor?

With mounting evidence for a role for cytokines in depression, macrophage migration inhibitory factor (MIF) has emerged as a strong candidate for a pathophysiological role. MIF is one of the first cytokines to be investigated, originally identified by its ability to prevent random migration of macrophages. It is released from intracellular pools by T- and B-lymphocytes, monocytes, macrophages, dendritic cells, neutrophils, eosinophils, mast cells, and basophils. It is also widely distributed in tissues [19]. Its release is triggered when cells are exposed to microbial products, pro-inflammatory cytokines, or specific antigens. Upon release, it acts in an autocrine and paracrine fashion to induce production of pro-inflammatory cytokines [20]. It also opposes the anti-inflammatory activity of glucocorticoids [21], which will be discussed later. Finally, it has been shown to have a role in cellular responses to DNA damage and cell cycle regulation [22]. MIF has been implicated in several disease conditions, including sepsis [23], acute respiratory distress syndrome [24], tuberculosis [25], and diabetes [26].

MIF has been shown to bind the transmembrane receptor CD74 and complex with CD44, with subsequent signal transduction via extracellular signal-regulated kinases (ERK1/ERK2), which are subtypes of mitogen-activated protein kinases (MAPK) [27]. This leads to several downstream effects that mediate the physiological effects of MIF. Particularly significant is the production of prostaglandin E2 (PGE2). Upregulation of phospholipase A2 (PLA2) is likely important in both the pro-inflammatory cascade and inhibition of glucocorticoid activity [28]. MIF also increases expression of TLR4, which is involved in immune responses to pathogenic bacteria as well as the pathogenesis of endotoxemia [29]. In addition, MIF promotes survival of pro-inflammatory cells by inhibition of the tumor suppressor p53 [30]. MIF has been shown bind and inhibit JUN-activation domain-binding protein 1 (Jab1), a coactivator of activator protein 1 (AP1), which is involved in cell growth. MIF also acts as an enzyme in vitro, showing D-dopachrome tautomerase and thiol protein oxidoreductase activities [31, 32].

There are multiple lines of research pointing to a role for MIF in the pathobiology of depression. These findings have (i) identified MIF expression in the brain, particularly in areas significant to the behavioral symptoms of depression; (ii) established the significance of the hypothalamic-pituitary-adrenal (HPA) axis in depression, with which MIF has an intricate relationship; (iii) shown an interaction between MIF and both lifestyle and pharmacological antidepressant treatments; (iv) determined a connection between MIF and neurogenesis, another important avenue of depression research; and (v) explored MIF as a biomarker in major depression and other mood disorders. There is still much uncertainty about MIF’s exact pathophysiologic role, and whether its activity promotes or obstructs pathological processes in depression. The goal of this review is to summarize current research on the topic, highlight evidence for MIF as a pro- or antidepressant, and address the potential for future developments in this area.

Although MIF was originally identified as a product of T-lymphocytes, it was later discovered to be ubiquitous, with especially high expression rates in epithelia and endocrine tissues [20]. Several studies have also highlighted MIF expression in the central nervous system (CNS). Immunostaining of bovine brain has established MIF expression in the subependymal astrocytes, CA3/CA4 pyramidal cells of the hippocampus, and granule cells of the dentate gyrus [33]. Similar techniques have been used to localize MIF expression in rat brain to choroid plexus epithelia, ventricular ependymal cells, and cerebral astrocytes; the presence of MIF mRNA in astrocytes and neurons has also been confirmed with in situ hybridization [34]. An analysis of rat brain by Bacher and colleagues revealed MIF expression in neurons of the cortex, hypothalamus, hippocampus, cerebellum, and pons [35]. Conboy et al. used immunohistochemistry to establish MIF expression in astrocytes and the subgranular zone of the hippocampus [36]. Interestingly, several of these areas contain proliferating or maturing cell populations, which is an important consideration for neurogenesis. There is significant regional association with glucocorticoid activation.

MIF has also been isolated in human brain tissue, with high levels of MIF mRNA expression in all regions [37]. Human neural MIF maintains high expression levels throughout life (compared to other tissues, whose levels decline with age), which has led some to propose a maintenance role for MIF in isomerization of reactive catecholamine metabolites to neuromelanin precursors [38]. Neuromelanin has been shown to be neuroprotective in the pathobiology of Parkinson’s disease due to its role as a scavenger and sink for toxic metabolites [39]. MIF has putative roles in several CNS inflammatory conditions, including multiple sclerosis [40] and cerebral ischemia-reperfusion injury [41], as well as being implicated in tumor growth in the CNS [19].

Extensive research has been done in identifying brain areas significant in depression. Schmidt and colleagues identified corticostriatal projection neurons as being essential for antidepressant response [42]. A 2008 review of neuroimaging, lesioning, and postmortem analyses posits a visceromotor network underlying the physiology of emotion and mood, with dysfunction in this circuit leading to the symptoms of depression [43]. This network involves interplay between the medial prefrontal cortex, amygdala, hippocampus, and various limbic structures. It is noteworthy that this circuit includes the hippocampus, one of the areas previously identified as showing high MIF expression. This model has been applied to deep brain stimulation, an emerging approach to treatment-resistant depression [44].

As mentioned above, MIF opposes the activity of glucocorticoids on the immune system. This activity of glucocorticoids is well understood, and oral corticosteroids are in use by 0.5% of the general population. Glucocorticoids are produced endogenously as cortisol and released by the adrenal glands upon stimulation by adrenocorticotropic hormone (ACTH), secreted by corticotropic cells of the anterior pituitary; those cells release ACTH in response to stimulation by hypothalamic corticotropin-releasing hormone (CRH). This process is called the HPA axis. Corticosteroids bind cytosolic receptors that dimerize and translocate to the nucleus, downregulating transcription of pro-inflammatory cytokines and decreasing production of prostaglandins [21]. These effects are mediated by interactions with NFkB [45], an important transcriptional regulator. Specifically, glucocorticoids upregulate expression of annexin 1 [46] and MAPK phosphatase 1 (MPK1) [47], which both cause downregulation of PLA2. In addition to being involved with the production of prostaglandins and leukotrienes from arachidonic acid, PLA2 also stimulates release of cytokines via Jun N-terminal kinases (JNK) [48].

As discussed above, MIF causes upregulation of PLA2, likely downstream of ERK1/2 signaling pathways [28]. It may also affect NFkB via its interaction with Jab1, which can lead to suppression of the inhibitory binding factor of NFkB (IkB) [22]. MIF is expressed in cells at every level of the HPA axis [49]. Its plasma levels follow a circadian rhythm that is comparable to that observed for plasma cortisol [21], and it is released from pituitary cells by CRH in a dose-dependent fashion [50]. Cortisol has also been shown to induce secretion of MIF with a bell-shaped dose response curve [51], in which high levels suppress MIF production. This seems to indicate a homeostatic balance between MIF and glucocorticoids, with the dominant species determining whether to promote immune responses (in infection) or dampen them (to protect from the harmful effects of inflammation).

It is well established that patients with MDD experience dysregulation of the HPA axis, manifesting as alterations in cortisol secretion and loss of suppression by dexamethasone [52, 53]. These abnormalities manifest in 40 to 60% of patients with MDD [54]. This HPA dysregulation is similar to the hormonal changes observed in Cushing’s disease, albeit to a lesser degree [55]; interestingly, Cushing’s patients experience a greater incidence of mood disorders, which resolve upon normalization of cortisol levels [56]. Although patients with MDD do not experience Cushingoid symptoms per se, strong associations have been found between the hypercortisolism of depression and physical changes associated with Cushing’s disease, including hippocampal atrophy, cognitive impairment, and abdominal obesity [55]. These hormonal changes seem to be related to adrenal hyperresponsiveness to ACTH [54] as well as altered responses to glucocorticoids, especially at the level of negative feedback in the pituitary [17].

The relationship between altered glucocorticoid signaling and depression has been reiterated in mouse models, although there is still insufficient evidence to substantiate a true ‘glucocorticoid receptor theory of depression’ [57], especially since roughly half of MDD patients do not manifest HPA abnormalities. However, HPA dysregulation may represent one pathway among many that converge to produce the symptoms of depression. Significantly, stress and corticosteroids have also been shown to inhibit hippocampal neurogenesis; this effect is reversed by antidepressants [58]. MIF’s role in this scheme has been investigated: Edwards et al. found that MIF levels were 40% higher in healthy volunteers who showed depressive symptoms on the Beck Depression Inventory (BDI), and elevated MIF was associated with decreased cortisol response to acute stress and lower morning cortisol values [59].

Antidepressant response is a commonly used paradigm in depression research. Since the pathobiology and genetics of depression remain unknown, and many of its symptoms are impossible to replicate in an animal model, it has become necessary to design experimental models based on reproducible responses to established antidepressant treatments [60, 61]. These models utilize both classical treatments, such as selective serotonin reuptake inhibitors (SSRIs) and electroconvulsive therapy (ECT), as well as new treatments like increased physical activity and deep brain stimulation [62].

MIF has been tested against traditional antidepressant treatments. An assay of motivated behavior has shown an association between the ERK1/2 pathway and responses to tricyclic antidepressants [63]. Conboy and colleagues determined that fluoxetine, a commonly administered SSRI [13], causes an increase in neurons immunoreactive for MIF. They also found that MIF knockout (KO) mice and mice given the MIF inhibitor [64] ISO-1 showed decreased neurogenesis after administration of fluoxetine. In addition, deletion of MIF resulted in increased depressive symptoms in the Porsolt forced swim test for behavioral despair (FST) and impairments in hippocampal spatial learning and memory in the Morris water maze. They concluded from these results that MIF is significant in the neurogenic effects of antidepressants [36].

Physical activity (PA) is emerging as an exciting new avenue of therapy for depression. PA has relatively few adverse effects, and can positively influence other physiological and psychological disorders. PA has been shown to be immunomodulatory, promoting expression of certain cytokines and immune cells and reducing others, as reviewed elsewhere [65]. PA also induces production of erythropoietin (EPO), a glycoprotein hormone involved in red blood cell hematopoiesis [66]. EPO and its receptor have recently been elaborated in the CNS [67], and they have been shown to have neurotrophic and neuroprotective effects [68].

Moon et al. found that the antidepressant effects of exercise were partially mediated by MIF, which they concluded functions as an antidepressant [69]. Using data from mRNA microarrays, they determined that both voluntary exercise and ECT induce MIF. Similar to the results from Conboy et al. [36], MIF^−/− mice showed increased depressive behavior and decreased antidepressant effects from exercise on the FST. Intracerebroventricular (icv) MIF administration had a direct antidepressant effect on the FST. They also analyzed gene expression patterns for brain-derived neurotrophic factor (BDNF), an important species in neurogenesis [70], and tryptophan hydroxylase-2 (Tph2), a rate-limiting enzyme in brain production of serotonin [71]. Both were upregulated in exercise and icv administration of MIF. Induction of Tph2 by MIF was matched with increased expression of serotonin in a recombinant cell line. It was further determined that these effects are all dependent on CD74 and ERK1/2, both established factors in MIF signal transduction [20, 64].

MIF is known to have a role in embryonic development and cellular proliferation. As mentioned above, it promotes cell growth and inhibits apoptosis via inhibition of p53, a tumor suppressor protein. Swant et al. established in fibroblasts that RhoA GTPase is an important link between MIF and cyclin D1, which promotes cell cycle progression by phosphorylation of Rb, another tumor suppressor protein [72]. Inactivation of Rb leads to disinhibition of E2F, which promotes synthesis of S phase proteins and subsequent cellular proliferation [73]. MIF directly stimulates activation of RhoA.

Ito and colleagues determined that MIF is an important factor in embryonic development of zebrafish, a commonly used model for embryogenesis. Using whole-mount in situ hybridization (WISH) they detected widespread MIF expression in embryonic structures, including eyes, tectum, branchial arches, and gut structures. Using antisense Morpholino-mediated knockdown (MO), they determined that MIF MO fish displayed a reproducible phenotype of abnormal development in eyes and cartilage structures, and, significantly, in brain structures such as the tectum and fourth ventricle [74]. Similar expression patterns have been observed in avian, murine, and other mammalian models [75‐77]. MIF has also been shown to promote proliferation and survival of neural stem progenitor cells in vitro[78].

It is notable that MIF expression in the brain is localized in regions of cellular proliferation. As discussed above, MIF expression has been found in proliferating cells of the subgranular zone of the hippocampus, and is modulated by treatments affecting neurogenesis (chronic stress, corticosteroids, and antidepressants). MIF deletion by genetics or inhibitors also attenuates both basal and induced neurogenesis [36]. Similarly, Moon et al. found that MIF induces the production of BDNF [69], whose role in neurogenesis is well-established [70]. A summary of results from significant animal studies of MIF and depression can be found in Table 1.

With inflammation implicated in pathophysiology of depression, several groups have examined cytokines as depression biomarkers [79]. Rodent studies have indicated that serum MIF increases in response to acute stress [49, 80]. Several groups have examined MIF levels in human serum in the context of depressive symptoms. A study of male undergraduate students presented with a public speaking task determined that subjects with mild to moderate depression on the BDI demonstrated higher baseline serum levels of MIF as well as increased lymphocytes [59, 81]. Similar results have been reported in pregnant women, where an association was determined between depressive symptoms and increased MIF. Increased serum MIF was also observed after an immune challenge in pregnant patients with depressive symptoms as measured by the Center for Epidemiologic Studies Depression Scale (CES-D) [82]. Interestingly, studies of healthy patients with negative mood symptoms as measured by the Zung self-rating depression scale (SDS) showed no significant association between serum MIF and SDS mood scores [83]; associations were found with IL-1β, a species known to be elevated in depression [84].

MIF has also been examined as a biomarker in the context of clinical depression. In a drug trial examining celecoxib add-on therapy to reboxetine (a norepinephrine reuptake inhibitor), MDD patients had an increased serum MIF at baseline with no change during treatment [85]. Similar results were found in an analysis of leukocyte mRNA expression in serum from participants in the Genome-based Therapeutic Drugs for Depression (GENDEP) project. In addition to observing increased MIF in MDD patients compared to healthy controls, the group also found that treatment responders had significantly higher levels of serum MIF than patients who resisted treatment. MIF levels were shown to reduce over time in this study, but this was not associated with treatment response [86]. Results of human studies with MIF and depression are summarized in Table 2.